Cloud is shining bright for TAKE

PUNE, INDIA: TAKE Solutions is exploring Microsoft Cloud Computing platform Azure to launch some of its upcoming solutions on Cloud. Clinical portal, for instance, is one area that it plans to take to the Cloud level.

Cloud computing is emerging as the new generation of technology and delivery that many companies are betting on. A flavor of its potential is evident in the way SaaS is picking up, but which at the same time, are being challenged with concerns on scale and security.

In a cloud paradigm, companies can purchase software or services hosted on remote computers owned and maintained by a third party instead of spending on expensive in-house mainframe computers and then accessing services via the Internet. As per some estimates, cloud computing services can touch revenues above $56 billion in 2009.

By 2013, such services are predicted to earn over $150 billion, according to a recent study by Gartner Inc., a global information technology research and advisory firm.

Another recent survey by the Pew Research Center, a Washington, D.C.-based think tank, however, showed in a news report that more than 50 per cent of its respondents said they were concerned with control and security of data.

"Cloud users were also apprehensive about possible sale of data by service providers, to be used for promotional purposes or targeted ads," the report added.

Answering the security challenge, which becomes all the more acute in a Pharma company’s data and document management or compliance efficiency, Ram Yeleswarapu, president and CEO, TAKE Solutions, says, “We are well experienced and poised to crack that part. That’s exactly where our years of experience in this domain makes us different from just any other vendor trying its hands on an industry where IP and data security are high-key areas. This would indeed be a barrier to entry.”

While the company is not averse to partnering with other cloud platforms, Microsoft becomes a first choice as many of its existing solutions are built on MS.

The company’s existing portfolio covers the entire drug life cycle from pre-IDA (Investigational New Drug) through submissions, publishing, documentation, regulatory compliance, to NDA (New Drug Approval) and PV(Pharmaco Vigilance) post the launch of a drug in the market. TAKE has been serving in the Life Sciences and SCM arena in 16 countries with more than 300 customers.